Navigation Links
Cystic Fibrosis - Orphan Drug Designation for Innovative Treatment Against Lung Infections by Axentis Pharma AG
Date:4/30/2009

ZURICH, Switzerland, April 30 /PRNewswire/ -- An innovative treatment for infections of the respiratory tract in cystic fibrosis patients has received orphan drug designation in the US. Axentis Pharma of Zurich, Switzerland announced today that this sought-after designation has been granted to its product candidate Fluidosomes-tobramycin, a therapeutic that will soon be tested in Phase II clinical trials. The company has now been granted orphan drug designation for this candidate in both Europe and the US.

Axentis Pharma (Switzerland) announced today that the Office of Orphan Products Development of the US Food and Drug Administration (FDA) has granted the orphan drug designation to its lead product candidate Fluidosomes-tobramycin. This drug is a liposomal formulation of tobramycin, an innovative treatment for infections of the respiratory tract in patients with cystic fibrosis that is delivered directly to the site of infection via standard nebulizers. Pre-clinical and Phase I clinical studies support improved safety and efficacy profiles for Fluidosomes-tobramycin as compared to currently marketed treatments for infections of the respiratory tract in patients with cystic fibrosis.

The orphan drug designation is granted with respect to treatment of pulmonary infections caused by Pseudomonas aeruginosa, a bacterium that is one of the most common causes of infections of the respiratory tract in patients with cystic fibrosis. Axentis Pharmas product candidate received the orphan drug designation for the US only two months after the application and less than one year after orphan designation in Europe was transferred to the company. Dr. Helmut Brunar, company CEO and President, comments: "The orphan drug designation for the US is very good news for affected patients as well as for Axentis Pharma's shareholders. Together with the Orphan Drug Designation that was already achieved last year in Europe, the US
'/>"/>

SOURCE Axentis Pharma AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Promising Cystic Fibrosis Compound on Track for Development
2. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
3. Pediatric Pulmonary Expert Comments on Study of Lung Transplants for Cystic Fibrosis
4. Cystic Fibrosis Foundation Reports Upward Trend for Key Health Outcomes
5. Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF
6. Lung Transplants in Cystic Fibrosis Patients With Life-Threatening Bacteria Sparks Debate at ISHLT Meeting
7. PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
8. PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
9. Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections
10. Mpex Initiates a Phase 2 Clinical Trial of Aerosol MP-376 in the Treatment of Chronic Bacterial Infections in Cystic Fibrosis Patients
11. The Ocean Becomes a Pipeline To A Cure for Cystic Fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... 14, 2014  Mylan Inc. (NASDAQ: MYL ) ... with Abbott (NYSE: ABT ... non-U.S. developed markets specialty and branded generics business ("the Assets") ... will receive 105 million shares of the combined company ... $50.20 on Friday, July 11, 2014, representing an approximately 21% ...
(Date:7/13/2014)... July 13, 2014  Eli Lilly and Company ... from its non-clinical study in genetically engineered mice ... the beta-amyloid antibody N3pG and beta-secretase inhibitor BACE ... more effective in removing clumps of amyloid-beta protein ... thought to lead to Alzheimer,s disease (AD) – ...
(Date:7/11/2014)... , July 11, 2014 The consumer ... evolving across industry sectors to better identify winning ... ways to engage with and understand consumers, as ... and make critical purchasing decisions. ... Practices, LLC, one area where organizations can observe ...
Breaking Medicine Technology:Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 2Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 3Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 4Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 5Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 6Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 7Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 8Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 9Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 10Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 11New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3New Technologies Transforming Consumer Marketing Research Playbook 2
... Further to its previously announced voluntary recall of 18 ... Actavis is encouraging consumers to return any product in ... Consumers with Actavis 25 mcg/h Fentanyl patches may ... and information. Actavis identified one lot of ...
... Symmetry Medical Inc. (NYSE: SMA ), a ... industry and other medical markets, announced today that it has ... effective November 3, 2010.  The credit facility includes an "accordion ... $300 million. The credit facility has a term of five ...
Cached Medicine Technology:Actavis Encourages Consumers to Return Fentanyl Transdermal System 25 mcg/h 2Actavis Encourages Consumers to Return Fentanyl Transdermal System 25 mcg/h 3Symmetry Medical Closes $200 Million Credit Facility 2Symmetry Medical Closes $200 Million Credit Facility 3
(Date:7/14/2014)... Institute (BTI) has entered into an agreement with ... to identify novel drug candidates for the detection ... BTI,s capabilities in novel antibody discovery and Roche,s ... opening up the possibility of improved treatment for ... , The collaboration makes use of BTI,s discovery ...
(Date:7/14/2014)... July 14, 2014 Secure Decisions, a ... is partnering with the Software Assurance Marketplace (SWAMP) to ... the software that drives everyday life. , The SWAMP, ... housed in the Morgridge Institute for Research, is funded ... advance software security practices by building a free facility ...
(Date:7/14/2014)... SUNDAY, July 13, 2014 (HealthDay News) -- Along with ... people with Alzheimer,s disease and other types of dementia, ... their quality of life, the researchers said. "These ... variety of benefits for people with dementia and their ... Lerner, of Case Western Reserve University and University Hospitals ...
(Date:7/14/2014)... physically active in middle age appears to help reduce ... dementia, suggest the findings from two new studies. ... various levels, especially in midlife, is beneficial for cognitive ... in an Alzheimer,s Association news release. "These are ... research is needed to determine the extent and nature ...
(Date:7/14/2014)... Amy Norton HealthDay Reporter ... who enjoy mentally stimulating games may have bigger brains and ... The study looked at the connection between playing games such ... adults in their 50s and 60s. Researchers found that ... performed better on tests of memory and other mental functions. ...
Breaking Medicine News(10 mins):Health News:A*STAR partners Roche to develop new cancer therapeutics 2Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 2Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 3Health News:Cataract Surgery a Plus for Someone With Dementia, Study Says 2Health News:Staying Active May Help Prevent Dementia 2Health News:Can Games, Puzzles Keep Aging Minds Sharp? 2Health News:Can Games, Puzzles Keep Aging Minds Sharp? 3
... Inc. (R) (HMS) has been closely following ... as it unfolds, especially its impact on ... yesterday on ARRA, even with the up-front investment required ... electronic health record (EHR) technology if they are to ...
... - Predictive medicine company PreMD Inc. (TSX: PMD; PREMF.pk) ... , "Over the last while we have faced significant ... not currently able to continue to finance our clinical ... CEO. "We will be moving to a skeleton staff ...
... Oncology, Inc. ("US Oncology" or "the,Company"), one of the ... million, EBITDA of $52.3 million, Adjusted EBITDA,of $55.2 million, ... of $64.2,million for the three months ended December 31, ... ended December 31, 2008, prior to a first quarter ...
... Coalition Seeks to Increase Public Awareness and Research to ... February 28 To Be Observed Around the World With ... BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) ... of organizations led by the National Organization for Rare ...
... Manitoba and CINCINNATI, Feb. 26, 2009 Reliance,Products LP ... announce that the U.S.,Environmental Protection Agency (EPA) has approved ... the removal of arsenic, the parasites,Cryptosporidium and Giardia, and ... http://www.newscom.com/cgi-bin/prnh/20090115/CLTH035LOGO-a ) , The EPA ...
... NEW YORK, Feb 26 Our faces are our ... emotions and are connected with three out of the ... But what happens when what you see in the ... Multimedia News Release, go to: http://www.prnewswire.com/mnr/aafprs/35820/ If you ...
Cached Medicine News:Health News:HMS Responds to American Recovery and Reinvestment Act of 2009 2Health News:PreMD Reduces Staffing, Operations - FDA Appeal Still in Process 2Health News:PreMD Reduces Staffing, Operations - FDA Appeal Still in Process 3Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 2Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 3Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 4Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 5Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 6Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 7Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 8Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 9Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 10Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 11Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 12Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 13Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 14Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 15Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 16Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 17Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 18Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 19Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 20Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 21Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 22Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 23Health News:BioMarin Supports Observance of Rare Disease Day February 28 2Health News:BioMarin Supports Observance of Rare Disease Day February 28 3Health News:BioMarin Supports Observance of Rare Disease Day February 28 4Health News:Reliance Products and Procter & Gamble Announce EPA Approval of New Claims for PUR Purifier of Water 2Health News:Reliance Products and Procter & Gamble Announce EPA Approval of New Claims for PUR Purifier of Water 3Health News:Video: Facing the Facts - What You Need to Know About Facial Plastic Surgery 2